Frontlight ResearchEarly access
Taking people in United StatesEarly phase 1
Imaging Mitochondrial Complex-I in Cocaine Use Disorder: a [F-18]BCPP-EF PET Study
Key facts
- Who runs it
- Rajesh Narendran
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 40 people, planned
- Started
- 4 Sept 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Treatments tested
- [F-18]BCPP-EF
- Record updated
- 14 September 2026
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Other criteria
- Cocaine use disorders (CUD)
- Males or females between 18 and 45 years old
- fulfill DSM-5 criteria for moderate or severe (4+ criteria) cocaine use disorder
- No lifetime DSM-5 schizophrenia, schizoaffective disorder, bipolar disorder, and developmental disorders
- No comorbid DSM-5 major depressive or severe anxiety disorders (including cocaine-induced mood and anxiety disorders) in the past 12 months
- No comorbid DSM-5 alcohol, opioids, sedative-hypnotics, hallucinogens, and inhalant use disorders in the past 12 months. Subjects with a moderate to severe DSM-5 cannabis use disorder will also be excluded
- Not currently on psychotropic or medical medications that can influence binding to MC-I (e.g., metformin) or CGM (e.g., insulin, GLP-1 agonists), or increase the risks associated with an arterial line (e.g., warfarin, clopidogrel, aspirin, naproxen, ibuprofen, etc.)
- No comorbid medical disorders that can influence the PET outcome measures (for example, MC-I binding is altered in Parkinson' disease, mild or major neurocognitive disorders, mitochondrial disorders, immune disorders; and CGM is altered in diabetes, severe hyperlipidemia, hypertension, obesity), or are a contraindication for blood sampling (anemia), or placement of an arterial line (history of deep vein thrombosis, pulmonary embolism, thrombocytopenia or thrombocytosis)
- Not currently pregnant or breast-feeding
- Not currently employed as radiation worker; or has not participated in a radiation-related research protocol within the previous year such that the total cumulative annual radiation dose (i.e., from participation in previous radioactive drug studies and this study) would exceed the radiation dose limits specified in the FDA regulations (i.e., 21 CFR 361.1) that govern the research use of radiotracers
- No medical or psychiatric contraindications to undergo an MRI scan (such as ferromagnetic tattoos/piercings, implants, medical equipment, history of gunshot, and claustrophobia); Healthy controls (HC)
- Males or females between 18 and 45 years old
- No DSM-5 psychiatric or substance use disorder other than tobacco use disorder
- 6 to 10 above
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Where in United States
- University of PittsburghPittsburgh, United StatesContact: Rajesh NarendranTaking people
About the trial
What the trial wants to find out
Studies proposed in this application will image mitochondrial Complex-I in cocaine use disorder (CUD) and matched healthy controls
The group in the trial
- PETTreatment being tested
\[F-18\]BCPP-EF
Treatment: [F-18]BCPP-EF
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Imaging Brain Energy Use in Cocaine Use Disorder: a [F-18]BCPP-EF PET Study
- Criteria questions
- Built from NCT07773649, who can take part
- Record updated
- 14 September 2026